HKSE - Delayed Quote HKD
Simcere Pharmaceutical Group Limited (2096.HK)
8.530
-0.270
(-3.07%)
At close: April 25 at 4:08:21 PM GMT+8
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
6,607,805
6,607,805
6,324,082
4,999,718
4,508,720
Cost of Revenue
1,623,652
1,623,652
1,327,404
1,079,983
899,927
Gross Profit
4,984,153
4,984,153
4,996,678
3,919,735
3,608,793
Operating Expense
4,257,652
4,257,652
4,422,047
3,687,923
3,018,910
Operating Income
726,501
726,501
574,631
231,812
589,883
Net Non Operating Interest Income Expense
20,392
20,392
25,459
-2,561
-107,481
Pretax Income
740,038
740,038
886,254
1,401,797
805,088
Tax Provision
26,088
26,088
-40,478
-97,124
140,801
Net Income Common Stockholders
714,761
714,761
930,868
1,507,096
669,534
Diluted NI Available to Com Stockholders
714,761
714,761
930,868
1,507,096
669,534
Basic EPS
0.27
0.27
0.36
0.58
0.26
Diluted EPS
0.27
0.27
0.36
0.58
0.26
Basic Average Shares
2,608,533.908
2,608,533.908
2,611,171.592
2,608,641.618
2,608,641.618
Diluted Average Shares
2,608,533.908
2,608,533.908
2,620,375.892
2,611,357.884
2,608,641.618
Total Operating Income as Reported
711,802
711,802
860,605
1,448,544
926,836
Total Expenses
5,881,304
5,881,304
5,749,451
4,767,906
3,918,837
Net Income from Continuing & Discontinued Operation
714,761
714,761
930,868
1,507,096
669,534
Normalized Income
721,018.354
721,018.354
686,779.750
930,408.250
361,642.164
Interest Income
54,960
54,960
59,867
68,287
26,248
Interest Expense
34,568
34,568
34,408
70,848
133,729
Net Interest Income
20,392
20,392
25,459
-2,561
-107,481
EBIT
774,606
774,606
920,662
1,472,645
938,817
EBITDA
1,084,200
1,084,200
1,204,309
1,724,452
1,161,146
Reconciled Cost of Revenue
1,623,652
1,623,652
1,327,404
1,079,983
899,927
Reconciled Depreciation
309,594
309,594
283,647
251,807
222,329
Net Income from Continuing Operation Net Minority Interest
714,761
714,761
930,868
1,507,096
669,534
Total Unusual Items Excluding Goodwill
-6,486
-6,486
325,451
768,917
373,152
Total Unusual Items
-6,486
-6,486
325,451
768,917
373,152
Normalized EBITDA
1,090,686
1,090,686
878,858
955,535
787,994
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-228.646
-228.646
81,362.750
192,229.250
65,260.164
12/31/2020 - 10/27/2020
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade